May 12, 2025

Golf Course Proximity Linked to Parkinson's Risk

Living within 1 to 3 miles of a golf course was associated with increased risk of Parkinson's disease, with the strongest associations in areas with vulnerable groundwater potentially exposed to pesticides.

Conexiant

May 09, 2025

Hand Movements Reveal Autism's Kinematic Signature

Machine learning algorithms can distinguish between patients with and without autism by analyzing finger movements during grasping tasks.

Conexiant

May 09, 2025

Sweetie, Stop: The Harm of Elderspeak

Explore how well-meaning but condescending language like “sweetie” and “dearie” can undermine the dignity of older adults.

KFF Health News

May 09, 2025

Self-Harm Risk Rises Prior to and Following Gabapentinoids 

Researchers tracked over 10,000 patients and found the risk of self-harm was highest before starting gabapentinoids and again shortly after stopping, highlighting key periods for clinical monitoring.

Conexiant

May 08, 2025

Medical Oddities: Tummy Time for Grown-Ups

This week’s research: tattoos misfire, tea heals, and tummy time makes a comeback.

Conexiant

May 07, 2025

COVID-19 Vaccination May Lower Fibromyalgia Risk, Study

A large matched-cohort study found that COVID-19 vaccination was linked to a reduced risk of developing fibromyalgia among survivors, particularly in men and those with depression or anxiety.

Conexiant

May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

May 01, 2025

Race, Sex Gaps Reshape Hearing Loss Landscape

A new study reveals significant disparities in hearing loss prevalence: 60.7% of White males are affected, compared with 29.2% of Black females.

Conexiant

April 30, 2025

FDA Approves FcRn Blocker for Broad gMG Use

The first FcRn blocker for both adult and pediatric generalized myasthenia gravis has been approved by the FDA, based on data showing sustained symptom improvement and IgG reduction in clinical trials.

Conexiant